Clinical dosimetric impact of Acuros XB and analytical anisotropic algorithm (AAA) on real lung cancer treatment plans : review

<p>Photon dose calculation algorithms in treatment planning system could affect the accuracy of dose delivery when tissue heterogeneity is involved along the beam path. Treatment planning for lung cancer is challenging, especially in the case of treatment plan involving small fields. The combi...

Full description

Bibliographic Details
Main Author: Suresh Rana
Format: Article
Language:English
Published: IJCTO 2014-02-01
Series:International Journal of Cancer Therapy and Oncology
Subjects:
Online Access:http://ijcto.org/index.php/IJCTO/article/view/67
Description
Summary:<p>Photon dose calculation algorithms in treatment planning system could affect the accuracy of dose delivery when tissue heterogeneity is involved along the beam path. Treatment planning for lung cancer is challenging, especially in the case of treatment plan involving small fields. The combination of low-density (air) medium and small fields cause charge particle disequilibrium nears the air/tissue interface. Beam modeling within the dose calculation algorithms must also employ an accurate method of accounting tissue heterogeneity corrections in order to avoid dose overestimation or underestimation. Analytical anisotropic algorithm (AAA) is one of the widely tested and validated dose calculation algorithms in external beam photon radiation therapy. Recently, Acuros XB (AXB) was made available for photon dose calculations, and several studies have demonstrated better dose prediction accuracy of the AXB over AAA. This article reviews the results from the treatment planning studies, which have investigated the clinical dosimetric impact of the AXB and AAA on real lung cancer treatment plans.</p><p>--------------------------------------</p><p><strong>Cite this article as:</strong> Rana S. Clinical dosimetric impact of Acuros XB and analytical anisotropic algorithm (AAA) on real lung cancer treatment plans: review. <em>Int J Cancer Ther Oncol</em> 2014; <strong>2</strong>(1):02019.</p><p><br /><strong>DOI</strong>: <a href="http://dx.doi.org/10.14319/ijcto.0201.9" target="_blank">http://dx.doi.org/10.14319/ijcto.0201.9</a></p>
ISSN:2330-4049